An industry imperiled by regulatory bottlenecks • AUGUST 2001 • VOLUME 19 • nature biotechnology 709 Stem and immune cell based treatments, tissue-engineered products, and customized gene therapy offer real hope to millions of patients that currently lack treatment options. As companies accelerate the commercialization of these products, it is increasingly clear that government… CONTINUE READING